Literature DB >> 8619471

Pelvic exenteration and its modifications.

M A Rodriguwz-Bigas1, N J Petrelli.   

Abstract

Since it was first reported in 1948, pelvic exenteration has been used in the treatment of advanced pelvic cancers. The original procedure has been modified in an attempt to preserve urinary or fecal continence. A literature review was performed on selected series of total pelvic exenterations and modified pelvic exenterations in order to assess and discuss the different types of pelvic exenterations and the indications, contraindications, morbidity, mortality, and results of these procedures. According to the series reviewed, morbidity after pelvic exenteration ranges between 32% and 84%, postoperative mortality ranges from 0% to 14%, and and 5-year survival varies from 23% to 68% These numbers indicate that total pelvic exenteration and its modifications are a complex group of surgical procedures with significant early and late postoperative morbidity and mortality. While the authors do feel that these findings indicate that pelvic exenteration should only be undertaken by experienced surgeons at specialized centers, the authors caution that, about all, their findings indicate that the potential curability of a patient with adjacent organ involvement should not be compromised by doing less than an en bloc resection.

Entities:  

Mesh:

Year:  1996        PMID: 8619471     DOI: 10.1016/s0002-9610(97)89572-4

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  Preoperative body mass index, 30-day postoperative morbidity, length of stay and quality of life in patients undergoing pelvic exenteration surgery for recurrent and locally-advanced rectal cancer.

Authors:  Jessica Beaton; Sharon Carey; Michael J Solomon; Ker-Kan Tan; Jane Young
Journal:  Ann Coloproctol       Date:  2014-04-25

2.  Role of pelvic exenteration in the management of locally advanced primary and recurrent rectal cancer.

Authors:  Koh Ye Xin; Deanna Wan Jie Ng; Grace Hwei Ching Tan; Melissa Ching Ching Teo
Journal:  J Gastrointest Cancer       Date:  2014-09

3.  Factors affecting hospital length of stay following pelvic exenteration surgery.

Authors:  Ying Guo; Eugene Chang; Mehtap Bozkurt; Minjeong Park; Diane Liu; Jack B Fu
Journal:  J Surg Oncol       Date:  2017-10-16       Impact factor: 3.454

4.  Modified supralevator pelvic exenteration for the treatment of locally advanced rectal cancer with vaginal and uterine invasion.

Authors:  André Roncon Dias; Sérgio Carlos Nahas
Journal:  Surg Today       Date:  2012-08-21       Impact factor: 2.549

5.  Major complications following exenteration in cases of pelvic malignancy: a 10-year experience.

Authors:  Dariusz Wydra; Janusz Emerich; Sambor Sawicki; Katarzyna Ciach; Andrzej Marciniak
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

6.  Minimally invasive surgery techniques in pelvic exenteration: a systematic and meta-analysis review.

Authors: 
Journal:  Surg Endosc       Date:  2018-07-17       Impact factor: 4.584

7.  Selection criteria for the radical treatment of locally advanced rectal cancer.

Authors:  Mansel Leigh Davies; Dean Harris; Mark Davies; Malcolm Lucas; Peter Drew; John Beynon
Journal:  Int J Surg Oncol       Date:  2011-10-13

Review 8.  Rectal cancer: a review.

Authors:  Mohammad Sadegh Fazeli; Mohammad Reza Keramati
Journal:  Med J Islam Repub Iran       Date:  2015-01-31

9.  Pelvic exenteration: experience from a rural cancer center in developing world.

Authors:  Sampada B Dessai; Satheesan Balasubramanian; Vijay M Patil; Santam Chakraborty; Atanu Bhattacharjee; Syam Vikram
Journal:  Int J Surg Oncol       Date:  2015-02-08

10.  Pelvic Exenteration for the Treatment of Locally Advanced Vulvar Cancer in South West Wales.

Authors:  Ganiy Opeyemi Abdulrahman; Nagindra Das; Thipparajapura V Chandrasekaran; Umesh Khot; Peter J Drew; Pradeep Bose; Jessica N Vet; Nasima Tofazzal; Shaun Roberts; Kerryn Lutchman Singh
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.